Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,173.9
-

 

  • STI Straits Times Index
    3,173.9
    -
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,608.4
    -3.8 (-0.24%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,453.3
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,412.9
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,538.7
    -
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,948.6
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,916.7M
  • Value: 1,458.8M
  • Rise: 93
  • Fall: 260
  • Unch: 419

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Jiutian Chemical0.102+0.010
Sembcorp Marine0.195-0.005
Anchor Resources0.032+0.008
Oceanus^0.040-0.003
Thomson Medical0.113+0.001
Frasers L&C Tr1.470-
Golden Agri-Res0.215-
Singtel2.430-
ThaiBev0.765-0.005
Mercurius0.060-0.010

World Indices

World Indices
Name Last Change
Nasdaq 13,850.0 -50.2
HSI 28,453.3
HSCEI 10,874.8
Jakarta 5,948.6
Nikkei 225 29,538.7
SSE Comp 3,412.9
Shanghai A 3,577.3
Shanghai B 244.8
KOSPI 3,135.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

CSL LTD CSL
Updated on 12 Apr 2021 (End of trading day)
Last (AUD): 265.500 Change: +2.100 High: 265.790 Remarks: -
Change (%): +0.80 Low: 263.500
Open 263.970 Yesterday's Close 263.4
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 454,160 Cumulative Value
 
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a 6.89118 Trailing EPS (AUD) e 8.36214 NAV (AUD) b 23.2188
PE a 38.528 Trailing PE f 31.750 Price / NAV b 11.4347
Dividend (AUD) d 2.933927 Cash In Hand (AUD) g 6.9005 Issued & Paid-up Shares c 455,120,000
Dividend Yield (%) d 1.105 Price / Cash In Hand g 38.475 Treasury Shares h -
Beta - 75 Daysi 1.334 R-Squared - 75 Days(%)i 50.78 Market Cap (M) 120,834.360
Beta - 500 Daysi 1.300 R-Squared - 500 Days (%)i 37.01 Enterprise Value (M) 125,632.779
Piotroski F Score 5 Exchange Code CSL Par Value ( AUD ) n.a.
52 Weeks Volatility (%) 20.97 Free Float (%) 99.9
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 05 Mar 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 16 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CSL LTD ASX 120,834.360 38.528 31.750 11.4347 1.105
Industry Biotechnology ASX 3,299.671 46.022 37.766 10.7036 1.038
Local Peer POLYNOVO LIMITED ASX 1,911.411 - - 86.7868 -
Local Peer MESOBLAST LTD ASX 1,445.291 - - 2.1500 -
Local Peer TELIX PHARMACEUTIC ASX 1,145.188 - - 14.4943 -
Local Peer IMUGENE LIMITED ASX 786.336 - - 12.5000 -
Local Peer OPTHEA LIMITED ASX 552.775 - - 2.7978 -
Local Peer ANTEOTECH LIMITED ASX 496.621 - - 80.3030 -
Local Peer IMMUTEP LTD ASX 299.200 - - 4.9280 -
Local Peer NEXT SCIENCE LTD ASX 291.301 - - 11.8859 -
Local Peer KAZIA THERAPEUTICS LIMITED ASX 225.951 - - 7.1314 -
Local Peer BIONOMICS LTD ASX 200.738 - - 12.5000 -
Local Peer NEUREN PHARMACEUTICALS LTD ASX 164.651 - - 6.8027 -
Local Peer LEAF RESOURCES LTD ASX 113.302 - - 9.2683 -
Other Local Peers CHIMERIC THERAPEUTICS LTD (ASX), CYNATA THERAPEUTICS LTD (ASX), GENETIC TECHNOLOGIES (ASX), ACTINOGEN MEDICAL LTD (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), MEMPHASYS LTD (ASX), PATRYS LIMITED (ASX), BIOTRON (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), ADALTA LTD (ASX), REGENEUS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), RHINOMED LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), CONSTELLATION TECHNOLOGIES LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), NANOLLOSE LTD (ASX), CRYOSITE (ASX), LIVING CELL TECHNOLOGIES (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Global Peer AMGEN INC NASDAQ 143,345.908 19.734 19.734 15.2350 2.582
Global Peer GILEAD SCIENCES INC NASDAQ 81,817.226 665.202 665.181 4.4950 4.169
Global Peer ILLUMINA INC NASDAQ 58,851.683 89.713 89.713 12.5376 -
Global Peer MODERNA INC NASDAQ 56,393.366 - - 22.0167 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 55,462.466 20.453 20.453 6.3847 -
Global Peer WUXI BIO HKEx 428,024.343 225.536 225.538 17.5550 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 50,905.898 14.490 14.490 4.6172 -
Global Peer BIOGEN INC NASDAQ 40,851.945 10.211 10.211 3.8178 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 34,078.638 56.478 56.478 2.9249 -
Global Peer BIONTECH SE SPON ADS EACH REP 1 ORD SHS NASDAQ 29,499.375 1,702.774 1,702.673 17.5746 -
Other Global Peers BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), SEAGEN INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), SINO BIOPHARM (HKEx), INCYTE CORPORATION (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), NOVAVAX INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ZAI LAB-SB (HKEx), NEUROCRINE BIOSCIENCES INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), EXELIXIS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), JOINN (HKEx), INTELLIA THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), OLINK HLDG AB SPON ADS EACH REP 1 ORD SHS (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), Lonza (SGX), BEAM THERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ARENA PHARMACEUTICALS INC (NASDAQ), GENSCRIPT BIO (HKEx), AGIOS PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SEER INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ARVINAS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ORGANOGENESIS HOLDINGS INC (NASDAQ), INSTIL BIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), 3SBIO (HKEx), XENCOR INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), NUVATION BIO INC (NYSE), MYRIAD GENETICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), MACROGENICS INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), PANDION THERAPEUTICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), VIVA BIOTECH (HKEx), CYTOKINETICS INC (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), FIBROGEN INC (NASDAQ), JW THERAP-B (HKEx), KINTOR PHARMA-B (HKEx), MYOVANT SCIENCES LTD (NYSE), PRELUDE THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), JACOBIO-B (HKEx), BIOATLA INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), IMMUNOVANT INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ALLOVIR INC (NASDAQ), IMMUNOGEN INC (NASDAQ), KYMERA THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), EDGEWISE THERAPEUTICS INC (NASDAQ), PRECIGEN INC (NASDAQ), MIMEDX GROUP INC (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ALECTOR INC (NASDAQ), HAOHAI BIOTEC (HKEx), ALPHAMAB-B (HKEx), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), OCUGEN INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), FRONTAGE (HKEx), STOKE THERAPEUTICS INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), VOR BIOPHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), SHATTUCK LABS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), AFFIMED N V (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), OMEROS CORP (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), NKARTA INC (NASDAQ), CURIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), VAXCYTE INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), HUMANIGEN INC (NASDAQ), PERSONALIS INC (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), ASCENTAGE-B (HKEx), CORTEXYME INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), JHBP-B (HKEx), ITEOS THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), PASSAGE BIO INC (NASDAQ), MERUS B V (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), INHIBRX INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), IMMATICS N V (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), CHIMERIX INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ATHIRA PHARMA INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), VAXART INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KADMON HLDGS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), AGENUS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), IVERIC BIO INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SINOMAB BIO-B (HKEx), NEOLEUKIN THERAPEUTICS INC (NASDAQ), IKENA ONCOLOGY INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), CHEMOMAB THERAPEUTICS LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), ALTIMMUNE INC (NASDAQ), AKOUOS INC (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), DPHARMA (Bursa), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), VERASTEM INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), GERON CORP (NASDAQ), AVROBIO INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), LEE'S PHARM (HKEx), ATRECA INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), XOMA CORP (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SESEN BIO INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), ADICET BIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), ASCLETIS-B (HKEx), SYROS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), ESSEX BIO-TECH (HKEx), LAVA THERAPEUTICS NV (NASDAQ), ATHERSYS INC (NASDAQ), SQZ BIOTECHNOLOGIES CO (NYSE), OUTLOOK THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), FREQUENCY THERAPEUTICS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), ONCORUS INC (NASDAQ), PORTAGE BIOTECH INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), IMMUNOME INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), INFINITY PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), KAMADA LTD (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), NEXTCURE INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), CABALETTA BIO INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), BIOVIE INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), LARIMAR THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), MEDICENNA THERAPEUTICS CORP (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), EQUILLIUM INC (NASDAQ), IMV INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), EVOGENE LTD (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), INMUNE BIO INC (NASDAQ), CHIASMA INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), ENZO BIOCHEM INC (NYSE), PIERIS PHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), AXCELLA HEALTH INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), GAIN THERAPEUTICS INC (NASDAQ), BIOMX INC (NYSE American), SIO GENE THERAPIES INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), CEL-SCI CORP (NYSE American), GALECTIN THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), IBIO INC (NYSE American), AZIYO BIOLOGICS INC (NASDAQ), METACRINE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SYNLOGIC INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), ORGENESIS INC (NASDAQ), LONGEVERON INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), APTEVO THERAPEUTICS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), VIRIDIAN THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), OTONOMY INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), LEAP THERAPEUTICS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), LUMOS PHARMA INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), AVALON GLOBOCARE CORP (NASDAQ), AIKIDO PHARMA INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), MERRIMACK PHARMACEUTICALS INC (NASDAQ), ADVAXIS INC (NASDAQ), UNI-BIO GROUP (HKEx), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ATYR PHARMA INC (NASDAQ), BIOCARDIA INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), KIROMIC BIOPHARMA INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), WINDTREE THERAPEUTICS INC (NASDAQ), REGENT PACIFIC (HKEx), SOLIGENIX INC (NASDAQ), CYCLACEL PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CYCLO THERAPEUTICS INC (NASDAQ), CT ENTERPRISE (HKEx), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), ORAGENICS INC (NYSE American), HISTOGEN INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ACORDA THERAPEUTICS INC (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), PRECIPIO INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), Suntar Eco-City (SGX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), BRIACELL THERAPEUTICS CORP (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), GEOVAX LABS INC (NASDAQ), INMED PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), BIOSINO BIO-TEC (HKEx), SENECA BIOPHARMA INC (NASDAQ), BENITEC BIOPHARMA INC (NASDAQ), SENESTECH INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+2.500
+0.95 %
10 Days -+0.110
+0.04 %
20 Days -+9.650
+3.77 %
Medium Term Return 3 Months --10.450
-3.79 %
6 Months --31.170
-10.51 %
1 Year --63.500
-19.30 %
Long Term Return 2 Years -+69.960
+35.78 %
3 Years 2.481+104.350
+66.29 %
5 Years 5.121+162.130
+161.80 %
Annualised Return Annualised --
+21.23 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 242.000 - 332.680 Change From 1 Year Low +23.500 % Change From 1 Year Low (%) +9.71
Change From 1 Year High -67.180 % Change From 1 Year High (%) -20.19
2 Years Range 189.140 - 342.750 Change From 2 Years Low +76.360 % Change From 2 Years Low (%) +40.37
Change From 2 Years High -77.250 % Change From 2 Years High (%) -22.54
5 Years Range 91.620 - 342.750 Change From 5 Years Low +173.880 % Change From 5 Years Low (%) +189.78
Change From 5 Years High -77.250 % Change From 5 Years High (%) -22.54
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
12 Apr 2021 263.970 265.790 263.500 265.500 454,160 -
09 Apr 2021 263.840 266.600 262.280 263.400 588,048 -
08 Apr 2021 264.780 265.940 262.100 265.940 520,729 -
07 Apr 2021 264.000 266.480 262.030 262.990 780,977 -
06 Apr 2021 263.250 264.850 261.570 263.600 820,936 -
01 Apr 2021 267.000 267.000 261.930 263.000 615,339 -
31 Mar 2021 264.900 266.990 262.520 264.650 775,013 -
30 Mar 2021 265.940 268.830 262.660 262.660 478,746 -
29 Mar 2021 267.660 268.680 265.020 265.390 431,762 -
26 Mar 2021 270.270 270.530 265.240 267.460 553,036 -
25 Mar 2021 265.230 270.920 264.800 269.830 948,267 -
24 Mar 2021 262.780 267.960 260.930 266.020 847,739 -
23 Mar 2021 260.940 262.380 256.500 261.000 532,443 -
22 Mar 2021 255.010 261.090 252.520 260.160 547,135 -
19 Mar 2021 255.000 255.600 251.910 253.950 2,297,688 -
18 Mar 2021 265.000 265.100 255.700 256.090 928,840 -
17 Mar 2021 261.260 262.720 258.780 261.000 575,325 -
16 Mar 2021 258.940 263.610 255.850 261.810 868,312 -
15 Mar 2021 252.910 257.990 252.555 255.850 629,918 -
12 Mar 2021 254.200 255.490 252.640 253.260 398,008 -
11 Mar 2021 253.880 255.000 250.030 253.900 746,647 -
10 Mar 2021 255.350 256.610 252.210 252.210 845,417 -
Summary
Current 2 Weeks
(26 Mar 2021 to 12 Apr 2021)		 270.270 270.530 261.570 265.500 6,018,746 -
Previous 2 Weeks
(12 Mar 2021 to 25 Mar 2021)		 254.200 270.530 252.640 269.830 8,573,675 -
4 Weeks from
(12 Feb 2021 to 11 Mar 2021)		 277.000 277.790 261.570 253.900 19,730,875 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.